FDA issues complete response letter for baricitinib for moderate to severe rheumatoid arthritis April 18, 2017
Pfizer presents allosteric inhibitors of IL-2-inducible T-cell kinase for inflammatory diseases April 11, 2017
Bristol-Myers Squibb presents prodrug of BMT-1438 for the treatment of rheumatoid arthritis April 5, 2017
Galapagos to study filgotinib in Sjogren's syndrome, ankylosing spondylitis and psoriatic arthritis April 4, 2017
RSS